Gene Uenishi is a Senior Scientist in the Discovery group and the research lead for GentiBio’s type 1 diabetes (T1D) program. Prior to joining GentiBio, Gene was a Scientist at BlueRock Therapeutics, where he developed an iPSC-derived regulatory T cell (Treg) program and helped establish the Immunology research group in Boston, MA. He started his career in biotech as a project consultant for Waisman Biomanufacturing assisting with tech transfer for Cynata Therapeutics’ first iPSC-derived mesenchymal stem cell therapy to treat graft-vs-host disease. He then moved to San Francisco to join Casebia Therapeutics where he established a novel gene editing platform for LT-HSCs, and lead T-cell engineering programs to cure autoimmune diseases. Gene received his B.A. in psychology from Carleton College and his Ph.D. in Cell and Molecular Pathology from University of Wisconsin – Madison, and holds a number of patents in the field of gene editing and iPSC technologies.
Gene Uenishi, PhD